1317 related articles for article (PubMed ID: 23527621)
41. Developing oncology biosimilars: an essential approach for the future.
Abraham J
Semin Oncol; 2013 Dec; 40 Suppl 1():S5-24. PubMed ID: 24267944
[TBL] [Abstract][Full Text] [Related]
42. [The story of biosimilars--chance or threat?].
Woroń J; Kocić I
Pol Merkur Lekarski; 2014 Nov; 37(221):311-5. PubMed ID: 25546996
[TBL] [Abstract][Full Text] [Related]
43. Biosimilars in rheumatology: current perspectives and lessons learnt.
Dörner T; Kay J
Nat Rev Rheumatol; 2015 Dec; 11(12):713-24. PubMed ID: 26282080
[TBL] [Abstract][Full Text] [Related]
44. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.
Markus R; Liu J; Ramchandani M; Landa D; Born T; Kaur P
BioDrugs; 2017 Jun; 31(3):175-187. PubMed ID: 28439817
[TBL] [Abstract][Full Text] [Related]
45. Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch.
Sagi S; Anjaneya P; Kalsekar S; Kottke A; Cohen HP
Drug Saf; 2023 Dec; 46(12):1391-1404. PubMed ID: 37902937
[TBL] [Abstract][Full Text] [Related]
46. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
47. Biosimilars: Hope and concern.
Emmanouilides CE; Karampola MI; Beredima M
J Oncol Pharm Pract; 2016 Aug; 22(4):618-24. PubMed ID: 26391898
[TBL] [Abstract][Full Text] [Related]
48. International Society of Oncology Pharmacy Practitioners global position on the use of biosimilars in cancer treatment and supportive care.
Frazer MB; Bubalo J; Patel H; Siderov J; Cubilla M; De Lemos M; Dhillon H; Harchowal J; Kuchonthara N; Livinalli A; Macedo R; Mwangi W; Nomura H; O'Connor S; Patterson M; Seadi Torriani M; Yim B; Chan A; Foreman E
J Oncol Pharm Pract; 2020 Apr; 26(3_suppl):3-10. PubMed ID: 32268831
[TBL] [Abstract][Full Text] [Related]
49. Pharmacovigilance of Biologics in a Multisource Environment.
Sagi S; Cohen HP; Woollett GR
J Manag Care Spec Pharm; 2017 Dec; 23(12):1249-1254. PubMed ID: 29172979
[TBL] [Abstract][Full Text] [Related]
50. [Biosimilars--opportunity or threat?].
Swierkot J
Wiad Lek; 2013; 66(2 Pt 2):200-5. PubMed ID: 25775818
[TBL] [Abstract][Full Text] [Related]
51. Biosimilars - terms of use.
Declerck P; Mellstedt H; Danese S
Curr Med Res Opin; 2015 Dec; 31(12):2325-30. PubMed ID: 26397731
[TBL] [Abstract][Full Text] [Related]
52. The regulatory framework of biosimilars in the European Union.
Minghetti P; Rocco P; Cilurzo F; Vecchio LD; Locatelli F
Drug Discov Today; 2012 Jan; 17(1-2):63-70. PubMed ID: 21856438
[TBL] [Abstract][Full Text] [Related]
53. Development of biosimilars.
Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
[TBL] [Abstract][Full Text] [Related]
54. Biosimilars: Rationale and current regulatory landscape.
Olech E
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
[TBL] [Abstract][Full Text] [Related]
55. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective.
Kurki P; Barry S; Bourges I; Tsantili P; Wolff-Holz E
Drugs; 2021 Nov; 81(16):1881-1896. PubMed ID: 34596876
[TBL] [Abstract][Full Text] [Related]
56. Biosimilar medicines used for cancer therapy in Europe: a review.
Santos SB; Sousa Lobo JM; Silva AC
Drug Discov Today; 2019 Jan; 24(1):293-299. PubMed ID: 30244082
[TBL] [Abstract][Full Text] [Related]
57. Biosimilar regulation in the EU.
Kurki P; Ekman N
Expert Rev Clin Pharmacol; 2015; 8(5):649-59. PubMed ID: 26294076
[TBL] [Abstract][Full Text] [Related]
58. [Knowledge about Biosimilars in Primary Care: a study by the Spanish Society of Primary Care Physicians (SEMERGEN)].
Micó-Pérez RM; Payares-Herrera C; Palomo-Jiménez PI; Sánchez-Fierro J; Avendaño-Solá C; Llisterri-Caro JL
Semergen; 2018 Sep; 44(6):380-388. PubMed ID: 29459003
[TBL] [Abstract][Full Text] [Related]
59. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
60. Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts.
Inotai A; Csanadi M; Petrova G; Dimitrova M; Bochenek T; Tesar T; York K; Fuksa L; Kostyuk A; Lorenzovici L; Omelyanovskiy V; Egyed K; Kalo Z
Biomed Res Int; 2018; 2018():9597362. PubMed ID: 29546072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
